Adverse Event Reviews: FDA Needs To Boost ‘Accuracy And Efficiency’
This article was originally published in The Pink Sheet Daily
Agency seeks academic institutions and commercial organizations with tools that can conduct automated analysis of case reports from FAERS data.
You may also be interested in...
Adverse event reports per year have quadrupled over the last decade, and FDA expects the reports to retain their importance even as new technology helps with drug safety monitoring.
A small start-up company has developed a technique to filter the data in FDA’s Adverse Events Reporting System (AERS) database, which it says provides a more accurate analysis of adverse event reports.
Pfizer alleges its associate director of statistics transferred 12,000 files from her company laptop ahead of move to Xencor. Company seeks a temporary restraining order to prevent her from disclosing confidential information, including information on Pfizer’s COVID-19 vaccine and monoclonal antibodies for treatment of cancer.